Companies / BOC Sciences / Ralinepag
BOC Sciences

Ralinepag | BOC Sciences

This active molecular is a Epoprostenol receptor agonist which is an investigational drug candidate developed by Arena and intended for the treatment of vasospastic diseases, for an example, Pulmonary Arterial Hypertension . Ralinepag has the potential to mimic prostacyclin which elicits a potent vasodilation and inhibits platelet aggregation when binding to this receptor. In Jan 2015, Phase-II clinical trials in Pulmonary arterial hypertension in USA was on going. In Jul 2015, Phase-II clinical trials in Pulmonary arterial hypertension in Spain was on going. In Jul 2015, Arena initiated enrolment in a phase II extension trial for Pulmonary arterial hypertension in USA, Czech Republic, Hungary, Poland.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.